Cheryl Cohen, an insider of ImmunityBio, Inc. (IBRX), reported transactions in the company’s common stock that occurred on July 2, 2026. The Form 4, filed July 6, shows both an option-related acquisition and an open-market sale of shares. Cohen exercised stock options to acquire 55,979 shares of ImmunityBio common stock at an exercise price of $2.98 per share. That transaction is typically reported under transaction code “M” for the exercise or conversion of derivative securities. The filing excerpt does not provide additional option grant, expiration, or vesting details beyond the share count and exercise price. On the same date, Cohen sold 131,210 shares of common stock at a weighted average price of $9.5034 per share. The sale was reported as taking place within a narrow price range of $9.50 to $9.52, and Cohen undertook to provide detailed price-by-price information upon request to the SEC, ImmunityBio, or a security holder. Based on the weighted average price, the sale generated approximately $1.25 million in gross proceeds. The filing states that the sale was made under a Rule 10b5-1 trading plan that Cohen entered into on February 27, 2026. Such plans allow insiders to schedule trades in advance under pre-set terms, providing an affirmative defense against claims that trades were made on the basis of material nonpublic information. After the reported transactions, the filing indicates Cohen beneficially owned 256,596 shares of ImmunityBio common stock. The report was signed on Cohen’s behalf by Philip LoScalzo as attorney-in-fact on July 6, 2026.